ADCC-Enhanced Anti-Human CD38 (MOR202) Antibody (CAT#: BioBet-CB-014LX) Datasheet

CD38

platelet derived growth factor receptor alpha

This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers.

Platelet Derived Growth Factor Receptor Alpha; Platelet-Derived Growth Factor Receptor; Alpha Polypeptide; Alpha-Type Platelet-Derived Growth Factor Receptor; Platelet-Derived Growth Factor Receptor 2; CD140 Antigen-Like Family Member A; CD140a Antigen; PDGF-R-Alpha; EC 2.7.10.1; PDGFR-2;

Cell Biology, Immunology,

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1

MOR202

Human

Human

ADCC-Enhanced Anti-Human CD38 (MOR202) Antibody is derived from clone MOR202, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the CD38, and it is intended for the research of Multiple myeloma.

Multiple myeloma

Similar to the parental antibody MOR202, ADCC-Enhanced Anti-Human CD38 (MOR202) Antibody targets to the antigen CD38, achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.